Reduced human igg anti-atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil

Jess A. Kimball, Mark D. Pescovitz, Benita K. Book, Douglas Norman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Exposure to the equine-derived polyclonal antithymocyte preparation, ATGAM, frequently elicits human anti-ATGAM antibody formation. The influence of concomitant immunosuppressants on this antiantibody response has not been established. We therefore evaluated IgG antibody formation to ATGAM in 47 patients receiving ATGAM as part of a prospective, randomized, double-blinded study of mycophenolate mofetil versus azathioprine for maintenance immunosuppression after primary cadaveric renal transplantation. All patients received ATGAM for induction of immunosuppression plus methylprednisolone, prednisone, and cyclosporine. In addition, patients were randomized to receive maintenance immunosuppression consisting of either azathioprine (AZA) 1-2 mg/kg/day, mycophenolate mofetil 2 gm/day (MMF2), or mycophenolate mofetil 3 gm/day (MMF3). Patient sequential sera were independently tested for IgG anti-ATGAM antibody by 2 laboratories, which were blinded to treatment arm assignments, using enzyme-linked immunosorbent assays. Both laboratories found significantly greater anti-ATGAM antibody formation in group AZA compared with groups MMF2 and MMF3: Laboratory 1 reported sensitization rates in the 3 groups of 94% (AZA), 50% (MMF2) (P

Original languageEnglish (US)
Pages (from-to)1379-1383
Number of pages5
JournalTransplantation
Volume60
Issue number12
StatePublished - Dec 27 1995

Fingerprint

Mycophenolic Acid
Antilymphocyte Serum
Antibody Formation
Anti-Idiotypic Antibodies
Kidney
Azathioprine
Immunosuppression
Immunoglobulin G
Maintenance
Methylprednisolone
Immunosuppressive Agents
Prednisone
Transplant Recipients
Kidney Transplantation
Cyclosporine
Horses
Enzyme-Linked Immunosorbent Assay
Serum

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Reduced human igg anti-atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil. / Kimball, Jess A.; Pescovitz, Mark D.; Book, Benita K.; Norman, Douglas.

In: Transplantation, Vol. 60, No. 12, 27.12.1995, p. 1379-1383.

Research output: Contribution to journalArticle

Kimball, Jess A. ; Pescovitz, Mark D. ; Book, Benita K. ; Norman, Douglas. / Reduced human igg anti-atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil. In: Transplantation. 1995 ; Vol. 60, No. 12. pp. 1379-1383.
@article{b4970e6f411e4a25821f002cd13ed518,
title = "Reduced human igg anti-atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil",
abstract = "Exposure to the equine-derived polyclonal antithymocyte preparation, ATGAM, frequently elicits human anti-ATGAM antibody formation. The influence of concomitant immunosuppressants on this antiantibody response has not been established. We therefore evaluated IgG antibody formation to ATGAM in 47 patients receiving ATGAM as part of a prospective, randomized, double-blinded study of mycophenolate mofetil versus azathioprine for maintenance immunosuppression after primary cadaveric renal transplantation. All patients received ATGAM for induction of immunosuppression plus methylprednisolone, prednisone, and cyclosporine. In addition, patients were randomized to receive maintenance immunosuppression consisting of either azathioprine (AZA) 1-2 mg/kg/day, mycophenolate mofetil 2 gm/day (MMF2), or mycophenolate mofetil 3 gm/day (MMF3). Patient sequential sera were independently tested for IgG anti-ATGAM antibody by 2 laboratories, which were blinded to treatment arm assignments, using enzyme-linked immunosorbent assays. Both laboratories found significantly greater anti-ATGAM antibody formation in group AZA compared with groups MMF2 and MMF3: Laboratory 1 reported sensitization rates in the 3 groups of 94{\%} (AZA), 50{\%} (MMF2) (P",
author = "Kimball, {Jess A.} and Pescovitz, {Mark D.} and Book, {Benita K.} and Douglas Norman",
year = "1995",
month = "12",
day = "27",
language = "English (US)",
volume = "60",
pages = "1379--1383",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Reduced human igg anti-atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil

AU - Kimball, Jess A.

AU - Pescovitz, Mark D.

AU - Book, Benita K.

AU - Norman, Douglas

PY - 1995/12/27

Y1 - 1995/12/27

N2 - Exposure to the equine-derived polyclonal antithymocyte preparation, ATGAM, frequently elicits human anti-ATGAM antibody formation. The influence of concomitant immunosuppressants on this antiantibody response has not been established. We therefore evaluated IgG antibody formation to ATGAM in 47 patients receiving ATGAM as part of a prospective, randomized, double-blinded study of mycophenolate mofetil versus azathioprine for maintenance immunosuppression after primary cadaveric renal transplantation. All patients received ATGAM for induction of immunosuppression plus methylprednisolone, prednisone, and cyclosporine. In addition, patients were randomized to receive maintenance immunosuppression consisting of either azathioprine (AZA) 1-2 mg/kg/day, mycophenolate mofetil 2 gm/day (MMF2), or mycophenolate mofetil 3 gm/day (MMF3). Patient sequential sera were independently tested for IgG anti-ATGAM antibody by 2 laboratories, which were blinded to treatment arm assignments, using enzyme-linked immunosorbent assays. Both laboratories found significantly greater anti-ATGAM antibody formation in group AZA compared with groups MMF2 and MMF3: Laboratory 1 reported sensitization rates in the 3 groups of 94% (AZA), 50% (MMF2) (P

AB - Exposure to the equine-derived polyclonal antithymocyte preparation, ATGAM, frequently elicits human anti-ATGAM antibody formation. The influence of concomitant immunosuppressants on this antiantibody response has not been established. We therefore evaluated IgG antibody formation to ATGAM in 47 patients receiving ATGAM as part of a prospective, randomized, double-blinded study of mycophenolate mofetil versus azathioprine for maintenance immunosuppression after primary cadaveric renal transplantation. All patients received ATGAM for induction of immunosuppression plus methylprednisolone, prednisone, and cyclosporine. In addition, patients were randomized to receive maintenance immunosuppression consisting of either azathioprine (AZA) 1-2 mg/kg/day, mycophenolate mofetil 2 gm/day (MMF2), or mycophenolate mofetil 3 gm/day (MMF3). Patient sequential sera were independently tested for IgG anti-ATGAM antibody by 2 laboratories, which were blinded to treatment arm assignments, using enzyme-linked immunosorbent assays. Both laboratories found significantly greater anti-ATGAM antibody formation in group AZA compared with groups MMF2 and MMF3: Laboratory 1 reported sensitization rates in the 3 groups of 94% (AZA), 50% (MMF2) (P

UR - http://www.scopus.com/inward/record.url?scp=0029588451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029588451&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 1379

EP - 1383

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -